Stem Point Capital LP Centessa Pharmaceuticals PLC Transaction History
Stem Point Capital LP
- $499 Billion
- Q3 2025
A detailed history of Stem Point Capital LP transactions in Centessa Pharmaceuticals PLC stock. As of the latest transaction made, Stem Point Capital LP holds 655,385 shares of CNTA stock, worth $18.1 Million. This represents 3.18% of its overall portfolio holdings.
Number of Shares
655,385
Previous 1,265,672
48.22%
Holding current value
$18.1 Million
Previous $16.6 Billion
4.44%
% of portfolio
3.18%
Previous 5.34%
Shares
5 transactions
Others Institutions Holding CNTA
# of Institutions
139Shares Held
125MCall Options Held
1.49MPut Options Held
787K-
Medicxi Ventures Management (Jersey) LTD20MShares$551 Million73.31% of portfolio
-
Avoro Capital Advisors LLC New York, NY10.8MShares$298 Million3.58% of portfolio
-
Adage Capital Partners Gp, L.L.C. Boston, MA10MShares$277 Million0.41% of portfolio
-
Index Venture Life Associates Vi LTD St. Helier, Y99.96MShares$275 Million100.0% of portfolio
-
General Atlantic LLC New York, NY9.68MShares$267 Million8.3% of portfolio
About Centessa Pharmaceuticals plc
- Ticker CNTA
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 94,339,296
- Market Cap $2.6B
- Description
- Centessa Pharmaceuticals plc, a clinical-stage pharmaceutical company, discovers, develops, and delivers medicines to patients. Its registrational pipeline products include Lixivaptan, a vasopressin V2 receptor small molecule inhibitor that is in Phase III clinical development for the treatment of autosomal dominant polycystic kidney disease; an...